Compare Gilead Sciences, Inc. (GILD) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Toronto-Dominion Bank — how do they compare? Gilead Sciences, Inc. trades at $134.8 (market cap $163.51B), while Toronto-Dominion Bank trades at $123.5 (market cap $203.96B). The key difference: Toronto-Dominion Bank is the larger of the two by market cap, and Toronto-Dominion Bank pays the higher dividend (2.53%). Which is the better fit depends on your goals.
| GILD | TD | |
|---|---|---|
Market Cap | $163.51B | $203.96B |
Sector | Health | Financials |
52-Week High | $155.80 | $124.80 |
52-Week Low | $108.22 | $72.55 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 2.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TD trades at $123.51, up 0.51% today, with a bullish technical signal from moving averages and a consensus analyst price target of $153.00. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $1.74 surpassing the $1.63 estimate. Revenue grew to $61.28 billion in 2025, and the company maintains a strong net income margin of 23.38%. A dividend of $1.12 per share is scheduled for payment on July 31, 2026.
The outlook for TD is positive, supported by earnings momentum and analyst confidence, though risks include volatile cash flows from operations and rising debt levels. The stock's current valuation at a P/E of 20.8 appears reasonable relative to growth, positioning it as a candidate for long-term dividend growth despite near-term overbought technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
